Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7

European Urology

Volumn 70, Issue 4, 2016, Pages 684-691

  Fosså, Sophie D ^a,b,c   Wiklund, Fredrik ^d   Klepp, Olbjørn ^e   Angelsen, Anders ^f   Solberg, Arne ^g   Damber, Jan Erik ^h   Hoyer, Morten ⁱ   Widmark, Anders ^j  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d KAROLINSKA INSTITUTE   (Sweden)

^e lesund Hospital   (Norway)

^f Urology Clinical Center   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

Antiandrogen monotherapy; High risk prostate cancer; Mortality; Radiotherapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; LEUPRORELIN; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADULT; ADVANCED CANCER; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONFORMAL RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; AGONISTS; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RADIATION DOSE FRACTIONATION; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCANDINAVIA; SURVIVAL RATE; TIME FACTOR;

AGED; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS; SCANDINAVIAN AND NORDIC COUNTRIES; SURVIVAL RATE; TIME FACTORS;

EID: 84961839481     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.03.021     Document Type: Article

References (31)

1. [1] D‘Amico, A.V., Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 60 (2002), 32–37.
2. [2] Thomsen, F.B., Brasso, K., Christensen, I.J., et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. Eur J Cancer 51 (2015), 1283–1292.
3. [3] Widmark, A., Klepp, O., Solberg, A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 373 (2009), 301–308.
4. [4] Mason, M.D., Parulekar, W.R., Sydes, M.R., et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 33 (2015), 2143–2149.
5. [5] Mottet, N., Peneau, M., Mazeron, J.J., Molinie, V., Richaud, P., Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: An open randomized phase 3 trial. Eur Urol 62 (2012), 213–219.
6. [6] Schröder, F.H., Hermanek, P., Denis, L., Fair, W.R., Gospodarowicz, M.K., Pavone-Macaluso, M., The TNM classification of prostate cancer. Prostate Suppl 4 (1992), 129–138.
7. [7] Scherr, D., Swindle, P.W., Scardino, P.T., National Comprehensive Cancer Network. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61:Suppl 1 (2003), 14–24.
8. [8] Widmark, A., Fosså, S.D., Lundmo, P., et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 61 (2003), 145–151.
9. [9] Gray RJ. Subdistribution analysis of competing risks. R package version 2.2-1. 2010 http://CRAN.R-project.org/package=cmprsk.
10. [10] Gray, R.J., A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
11. [11] Aalen, O., Nonparametric estimation of partial transition probabilities in multiple decrement models. Ann Statist 6 (1978), 534–545.
12. [12] Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
13. [13] Soloway, M.S., Matzkin, H., Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 71 (1993), 1083–1088.
14. [14] Ahmadi, H., Daneshmand, S., Androgen deprivation therapy for prostate cancer: Long-term safety and patient outcomes. Patient Relat Outcome Meas 5 (2014), 63–70.
15. [15] Briganti, A., Joniau, S., Gontero, P., et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 61 (2012), 584–592.
16. [16] Joniau, S., Hsu, C.Y., Gontero, P., Spahn, M., Van Poppel, H., Radical prostatectomy in very high-risk localized prostate cancer: Long-term outcomes and outcome predictors. Scand J Urol Neph 46 (2012), 164–171.
17. [17] Sundi, D., Wang, V.M., Pierorazio, P.M., et al. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis 17 (2013), 57–63.
18. [18] Epstein, J.I., Egevad, L., Amin, M.B., et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40 (2016), 244–252.
19. [19] Verhagen, P.C., Schröder, F.H., Collette, L., Bangma, C.H., Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 58 (2010), 261–269.
20. [20] Solberg, A., Haugen, O.A., Viset, T., et al. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys 80 (2011), 55–61.
21. [21] Roach, M.3rd, Bae, K., Speight, J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26 (2008), 585–591.
22. [22] Horwitz, E.M., Bae, K., Hanks, G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008), 2497–2504.
23. [23] Boorjian, S.A., Karnes, R.J., Viterbo, R., et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117 (2011), 2883–2891.
24. [24] Abdollah, F., Schmitges, J., Sun, M., et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol 19 (2012), 836–844.
25. [25] Sooriakumaran, P., Nyberg, T., Akre, O., et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: Observational study of mortality outcomes. BMJ 348 (2014), 1–13.
26. [26] Ward, J.F., Slezak, J.M., Blute, M.L., Bergstralh, E.J., Zincke, H., Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005), 751–756.
27. [27] Zwergel, U., Suttmann, H., Schroeder, T., et al. Outcome of prostate cancer patients with initial PSA ≥20 ng/ml undergoing radical prostatectomy. Eur Urol 52 (2007), 1058–1066.
28. [28] Yossepowitch, O., Eastham, J.A., Radical prostatectomy for high-risk prostate cancer. World J Urol 26 (2008), 219–224.
29. [29] Stephenson, A.J., Kattan, M.W., Eastham, J.A., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27 (2009), 4300–4305.
30. [30] Pierorazio, P.M., Ross, A.E., Han, M., Epstein, J.I., Partin, A.W., Schaeffer, E.M., Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. Br J Urol Int 109 (2011), 988–993.
31. [31] Fransson, P., Lund, J.A., Damber, J.E., et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomized, phase III trial. Lancet Oncol 10 (2009), 370–380.